Overview

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Status:
Not yet recruiting

Trial end date:
2027-07-15

Target enrollment:

Participant gender:

Summary

This is a prospective, single arm, open-label, exploratory study in women with primary operable HER2-positive, HER2-enriched(HER2-E)/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff (high vs low ERBB2 expression), to evaluate the omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab.

Phase:

Phase 2

Details

Lead Sponsor:

David Garcia Cinca

Collaborator:

Fundacion Clinic per a la Recerca Biomédica

Treatments:

Paclitaxel
Pertuzumab
Trastuzumab